Your browser doesn't support javascript.
loading
Phased implementation of COVID-19 vaccination: rapid assessment of policy adoption, reach and effectiveness to protect the most vulnerable in the US
Yun Li; Moming Li; Megan Rice; Yanfang Su; Chaowei Yang.
Afiliação
  • Yun Li; george mason university
  • Moming Li; University of California at San Francisco
  • Megan Rice; Carnegie Mellon University
  • Yanfang Su; Washington University
  • Chaowei Yang; George Mason University
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21252118
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
ObjectivesThe US and rest of the world have suffered from the COVID-19 pandemic for over a year. The high transmissibility and severity of this virus have provoked governments to adopt a variety of mitigation strategies. Some of these previous measures, such as social distancing and mask mandates, were effective in reducing the case growth rate yet became economically and administratively difficult to enforce as the pandemic continued. In late December 2020, COVID-19 vaccines were first approved in the US and states began a phased implementation of COVID-19 vaccination. However, there is limited quantitative evidence regarding the effectiveness of the phased COVID-19 vaccination. This study aims to provide a rapid assessment of the adoption, reach, and effectiveness of the phased implementation of COVID-19 vaccination. MethodsWe utilize an event-study analysis to evaluate the effect of vaccination on the state-level, daily COVID-19 case growth rate. ResultsThrough this analysis, we assert that vaccination is effective in reducing the spread of COVID-19 shortly after the first shots were given. Specifically, the case growth rate declined by 0.124, 0.347, 0.345, 0.464, 0.490, and 0.756 percentage points corresponding to the 1-5, 6-10, 11-15, 16-20, 21-25, and 26 or more day periods after the initial shots. ConclusionsThe findings could be insightful for policymakers as they work to optimize vaccine distribution in later phases, and also for the public as the COVID-19 related health risk is a contentious issue.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...